NaV1.7 selective backup therapuetic - Channel Therapeutics Corporation
Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Chromocell Corporation
- Developer Channel Therapeutics Corporation
- Class Analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain